Clinical Trials Logo

Glaucoma, Open-Angle clinical trials

View clinical trials related to Glaucoma, Open-Angle.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06061718 Active, not recruiting - Ocular Hypertension Clinical Trials

Travoprost Intraocular Implant in Conjunction With Cataract Surgery

Start date: September 11, 2023
Phase: Phase 3
Study type: Interventional

Subjects with cataract requiring extraction and who have open-angle glaucoma or ocular hypertension will undergo screening and washout from IOP-lowering medication, if applicable. Eligible subjects who meet all inclusion criteria and none of the exclusion criteria and who undergo successful cataract extraction with implantation of a posterior chamber intraocular lens (PC-IOL) will receive a travoprost intraocular implant and followed up for 12 months.

NCT ID: NCT05932940 Active, not recruiting - Angle Glaucoma Open Clinical Trials

Incidence of Descemet Membrane Detachment Post GATT by AS OCT

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

detection of Incidence of Descemet membrane detachment post gonioscopy-assisted transluminal trabeculotomy by anterior segment optical coherence tomography in patients with open angle glaucoma.

NCT ID: NCT05498103 Active, not recruiting - Clinical trials for Glaucoma, Open-Angle

Use of Methazolamide to Lower Intraocular Pressure

Start date: February 17, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect of methazolamide, 25 mg or 50 mg tablets once a day for a week than twice a day for a week, on lowering intraocular pressure and the safety of methazolamide.

NCT ID: NCT05456724 Active, not recruiting - Ocular Hypertension Clinical Trials

A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start date: August 4, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II stage to investigate the safety, tolerability, and ocular hypotensive efficacy of TO-O-1001 in healthy volunteers and patients with Open-Angle Glaucoma or Ocular Hypertension. The proposed trial consists of 3 study parts to be conducted at Nucleus Network Melbourne. This study will enroll up to 34 evaluable healthy volunteers in part 1(SAD) and part 2(MD) and 16 evaluable patients with Open-Angle Glaucoma or Ocular Hypertension in part 3(MD). Note- As of 14Mar2023, enrolment has been completed for Part 1 and Part 2 and recruitment is pending now for Part 3.

NCT ID: NCT05335122 Active, not recruiting - Ocular Hypertension Clinical Trials

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Start date: March 16, 2022
Phase: Phase 2
Study type: Interventional

To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)

NCT ID: NCT05236439 Active, not recruiting - Clinical trials for Glaucoma, Open-Angle

Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma

SAFARI 3
Start date: May 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and primary narrow angle glaucoma (PNAG) who have failed at least one class of topical medical therapy

NCT ID: NCT05160805 Active, not recruiting - Open Angle Glaucoma Clinical Trials

A Phase 1b Study of ONL1204 Ophthalmic Solution in Patients With Progressing Open Angle Glaucoma

Start date: May 2, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to demonstrate the safety and tolerability of ONL1204 Ophthalmic Solution in patients with progressing open angle glaucoma. ONL1204 Ophthalmic Solution is a first-in-class inhibitor of fragment apoptosis stimulator (Fas) receptor-mediated cell death that has demonstrated protection of multiple retinal cell types in numerous preclinical models of retinal disease. Apoptosis of retinal ganglion cells is associated with progressive glaucoma. Nonclinical data on ONL1204 Ophthalmic Solution suggest that ONL1204 Ophthalmic Solution may inhibit the cell death pathways in these cells.

NCT ID: NCT05159817 Active, not recruiting - Clinical trials for Glaucoma, Open-Angle

Study of an Interposition Supraciliary Implant in Patients With Open Angle Glaucoma

SAFARI FU
Start date: December 15, 2021
Phase:
Study type: Observational

The purpose of this study is to prolong observational follow-up up to 36 months of patients already implanted with a novel interposition supraciliary implant.

NCT ID: NCT05130554 Active, not recruiting - Surgery Clinical Trials

XEN45 in the Treatment of Chinese Patients With Primary Open-angle Glaucoma

Start date: November 7, 2021
Phase: N/A
Study type: Interventional

Glaucoma is the second most common blindness disease in the world, second only to cataracts. The current treatment of glaucoma is mainly to reduce intraocular pressure.At present, two commonly used surgical methods are trabeculectomy and implantation of drainage valve. These methods are superior to drug treatment in reducing intraocular pressure, but the effect duration of these two methods is not long, and there may be serious complications and failure. Compared with traditional glaucoma surgery, MIGS may have better safety.The XEN45 gel implant is a collagen tube with a length of 6 mm and a diameter of 45 µm, which creates a new channel for drainage of aqueous humor by connecting the anterior chamber and the subconjunctival space. The implant is composed of porcine gelatin cross-linked with glutaraldehyde, and has good biocompatibility and tolerance. Therefore, after the advent of XEN45 products, more and more studies have shown that this treatment has excellent safety and effectiveness in reducing intraocular pressure in patients with open-angle glaucoma. Considering that the XEN45 gel stent has been in the market for a relatively short time, we conducted this prospective study to investigate the effect of XEN45 surgery in the treatment of primary open-angle glaucoma, in order to support ophthalmologists in formulating the best surgical plan for patients. The promotion of this surgical method.

NCT ID: NCT05127551 Active, not recruiting - Glaucoma Clinical Trials

Clinical Study of Glaukos® Trabecular Micro-Bypass System Model iS3 Infinite Vs. Competitor

Start date: November 27, 2021
Phase: N/A
Study type: Interventional

A study of the iStent Infinite product in the treatment of open-angle glaucoma vs competitor